Segmental excision versus intralesional curettage with adjuvant therapy for giant cell tumour of bone
To the Editor:
We read with interest the article by Yacob et al. 1 The authors concluded that local recurrence of giant cell tumour (GCT) of bone was not associated with surgical option. Can the authors advise whether any patient had pathological fracture; what the characteristics of the pathological fracture were, for example timing, displacement pattern, and intraarticular extension. Did patients with pathological fracture have a similar outcome to those without? What was the outcome following curettage? In one study, patients with and without a pathological fracture at the time of presentation have a comparable local recurrence rate. 2 The presence of a pathological fracture should not preclude the option of curettage. 2 Was the outcome different in patients with GCT of the ulna or radius? Most such tumours are resected rather than curetted. 3 Was there any adjuvant used following curettage and was burr used to provide extended curettage? 
